X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA BIOCON LTD NATCO PHARMA/
BIOCON LTD
 
P/E (TTM) x 33.0 36.5 90.3% View Chart
P/BV x 16.8 4.9 345.8% View Chart
Dividend Yield % 0.7 1.5 44.7%  

Financials

 NATCO PHARMA   BIOCON LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
BIOCON LTD
Mar-16
NATCO PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs877496 176.9%   
Low Rs424397 106.8%   
Sales per share (Unadj.) Rs223.4174.3 128.2%  
Earnings per share (Unadj.) Rs31.144.8 69.3%  
Cash flow per share (Unadj.) Rs40.356.9 70.8%  
Dividends per share (Unadj.) Rs5.005.00 100.0%  
Dividend yield (eoy) %0.81.1 68.6%  
Book value per share (Unadj.) Rs219.5202.8 108.2%  
Shares outstanding (eoy) m33.07200.00 16.5%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.6 113.7%   
Avg P/E ratio x20.910.0 210.2%  
P/CF ratio (eoy) x16.17.8 206.0%  
Price / Book Value ratio x3.02.2 134.7%  
Dividend payout %16.111.2 144.2%   
Avg Mkt Cap Rs m21,50489,220 24.1%   
No. of employees `000NA4.4 0.0%   
Total wages/salary Rs m1,1286,363 17.7%   
Avg. sales/employee Rs ThNM7,894.5-  
Avg. wages/employee Rs ThNM1,441.2-  
Avg. net profit/employee Rs ThNM2,029.7-  
INCOME DATA
Net Sales Rs m7,38934,854 21.2%  
Other income Rs m167845 19.8%   
Total revenues Rs m7,55635,699 21.2%   
Gross profit Rs m1,7938,200 21.9%  
Depreciation Rs m3042,423 12.6%   
Interest Rs m366102 359.0%   
Profit before tax Rs m1,2906,520 19.8%   
Minority Interest Rs m46-744 -6.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m3092,569 12.0%   
Profit after tax Rs m1,0278,961 11.5%  
Gross profit margin %24.323.5 103.2%  
Effective tax rate %23.939.4 60.7%   
Net profit margin %13.925.7 54.1%  
BALANCE SHEET DATA
Current assets Rs m3,68139,932 9.2%   
Current liabilities Rs m3,12316,276 19.2%   
Net working cap to sales %7.667.9 11.1%  
Current ratio x1.22.5 48.0%  
Inventory Days Days8954 167.1%  
Debtors Days Days5986 68.1%  
Net fixed assets Rs m7,68539,101 19.7%   
Share capital Rs m3311,000 33.1%   
"Free" reserves Rs m6,67038,591 17.3%   
Net worth Rs m7,25940,556 17.9%   
Long term debt Rs m95520,724 4.6%   
Total assets Rs m11,95784,816 14.1%  
Interest coverage x4.564.9 7.0%   
Debt to equity ratio x0.10.5 25.7%  
Sales to assets ratio x0.60.4 150.4%   
Return on assets %11.710.7 109.1%  
Return on equity %14.222.1 64.1%  
Return on capital %20.719.0 109.2%  
Exports to sales %39.430.7 128.0%   
Imports to sales %5.720.4 28.0%   
Exports (fob) Rs m2,90810,717 27.1%   
Imports (cif) Rs m4217,105 5.9%   
Fx inflow Rs m3,44511,789 29.2%   
Fx outflow Rs m7038,393 8.4%   
Net fx Rs m2,7433,396 80.8%   
CASH FLOW
From Operations Rs m1,4405,264 27.4%  
From Investments Rs m-1,089-9,540 11.4%  
From Financial Activity Rs m-35310,867 -3.2%  
Net Cashflow Rs m-16,591 -0.0%  

Share Holding

Indian Promoters % 52.0 40.4 128.8%  
Foreign collaborators % 1.5 20.6 7.1%  
Indian inst/Mut Fund % 7.8 8.4 93.3%  
FIIs % 16.6 10.7 155.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 19.9 130.7%  
Shareholders   25,395 109,995 23.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS